dr. ramalingam on flaura trial results in egfr-mutant nsclc
Published 4 years ago • 298 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
2:09
dr. hassan on flaura trial results in egfr-mutant nsclc
-
1:29
dr. fidler on the flaura trial in egfr-mutant nsclc
-
5:52
treatment of egfr nsclc after osimertinib
-
9:44
breakthrough status in lung cancer, fast track status in lung cancer, and 2019 wclc highlights
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:23
flaura trial demonstrates efficacy in egfr-positive lung cancer
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
7:00
flaura trial: impact of os data in advanced nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
8:55
suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
-
0:57
examining the impact of the flaura trial in egfr-mutant nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
1:34
dr. ramalingam on new data for egfr inhibitors for lung cancer